HYBRID EVENT: Join us in person in Singapore or attend virtually from anywhere.
3rd Edition of International Cancer & Immuno-Oncology Conference
March 15-17, 2027 | Singapore
Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy.
Genetic Testing and Biomarkers: Use of genetic profiling in risk assessment and targeted therapy.
Genetic testing and biomarkers are reshaping cancer care through risk stratification and precision medicine. Advances in genetic profiling enable the identification of hereditary cancer syndromes, guiding preventive measures and early interventions. Biomarkers such as PD-L1, HER2, and EGFR are integral to targeted therapies, improving efficacy and reducing side effects. Liquid biopsy and genomic sequencing provide real-time monitoring of cancer progression and treatment response. Research focuses on discovering novel biomarkers and expanding the utility of genetic testing, making cancer care more individualized and effective.
Committee Members
Jianhua Luo
University of Pittsburgh School of Medicine, United States
Atif A Ahmed
Seattle Children’s Hospital, United States
Rajvir Dahiya
University of California San Francisco, United StatesCIOC 2027 Speakers
Thomas Jay Webster
Brown University, United States
Eleni Petsalaki
University of Crete, Greece
Title : Long-read sequencing reveals dynamic features of human malignancies
Jianhua Luo, University of Pittsburgh School of Medicine, United States
Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States